CG Oncology, Inc.
CGON Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$62.94
KIRA · Stoqly’s AI analyst, in plain words
- CG Oncology, Inc. had $4.0M of revenue in fiscal 2025, up 254.7% on the year before.
- Its operating margin was −4,722.1%, up 5,345.1 pts: of every 100 in sales, about −4,722 is left after running the business.
- CG Oncology, Inc. lost $161M in fiscal 2025.
- Free cash flow was −$132M in fiscal 2025, −3,279.2% of revenue.
- CG Oncology, Inc. has $739M more cash than debt.
Market cap
$5.6B
P/E
—
Revenue
$4.0M
Net income
−$161M
Free cash flow
−$132M
Operating margin
−4,722.1%
CG Oncology, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+254.7%
Yes. Sales grew 254.7% last year.
Does it make a profit?
−3,985.0%
No. It lost money last year.
Does profit turn into cash?
−3,279.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What CG Oncology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- CG Oncology, Inc.
- CIK
- 0001991792
CG Oncology, Inc. · CGON
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $0.2M | $1.1M | $4.0M |
| Revenue growth | — | 458.3% | 254.7% |
| Operating margin | −27,180.9% | −10,067.3% | −4,722.1% |
| Net income | −$48.6M | −$88.0M | −$161M |
| Net margin | −23,827.0% | −7,729.5% | −3,985.0% |
| Diluted EPS | −$15.65 | −$1.41 | −$2.08 |
| Cash | |||
| Cash from operations | −$45.7M | −$78.7M | −$132M |
| Capital expenditure | — | $0.2M | $0.1M |
| Free cash flow | — | −$78.9M | −$132M |
| FCF margin | — | −6,931.3% | −3,279.2% |
| Share count change | — | 1,343.0% | 23.7% |
| Debt and strength | |||
| Cash and short-term investments | $188M | $742M | $742M |
| Debt incl. finance leases | — | $0.0M | $3.0M |
| Shareholders' equity | −$123M | $733M | $753M |
| Current ratio | 13.6x | 35.3x | 24.6x |
| Returns and quality | |||
| Return on capital | — | — | −1,120.8% |
| Return on equity | — | −28.9% | −21.7% |
| Return on tangible equity | — | −12.0% | −21.7% |
| Piotroski F-score | — | 4 | 2 |
| Altman Z'' | −7.0 | 40.4 | 23.1 |
Insiders bought, 12 months
$24.8M
1 insider
Insiders sold, 12 months
$4.8M
2 insiders
Of sales under plans
100%
$4.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CG Oncology, Inc. · CGON
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $62.94 a share, the company is worth $5.6B.
Source: SEC EDGAR XBRL filings (CIK 0001991792). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.